Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
Our results demonstrated that both guselkumab and risankizumab were effective in patients who had previously failed other biologics. Clinical outcomes in both the guselkumab and risankizumab groups had remained unaffected during prior biologic treatments, including anti-TNF, anti-IL17, and/or anti-IL12/23. Treatments yielded consistent outcomes regardless of factors such as obesity, gender, and comorbidities.
Authors
- Hande Ermiş Akkuş (ORCID: https://orcid.org/0000-0002-1431-2203)
- Leyla Baykal Selçuk (ORCID: https://orcid.org/0000-0001-7956-4033)
- Deniz Aksu Arıca (ORCID: https://orcid.org/0000-0003-3755-4325)
- Burak Akşan (ORCID: https://orcid.org/0000-0002-3052-5014)
Institutions
- Giresun University (TR)
- Karadeniz Technical University (TR)
Publication Details
- Journal
- Anais Brasileiros de Dermatologia
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.abd.2024.05.005
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59